Trials / Unknown
UnknownNCT05323318
Neuropsychological Sequelae and Long COVID-19 Fatigue
Neuropsychological Sequelae as a Risk Factor for Long COVID-19 Fatigue
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Centro Hospitalar Universitario do Algarve · Academic / Other
- Sex
- All
- Age
- 18 Years – 95 Years
- Healthy volunteers
- —
Summary
An association of fatigue with post-viral neuropsychological disturbs has been reported. Among patients hospitalized with COVID-19 there is an increased incidence of anxiety and depression symptoms. In addition, a quarter of patients experience at least mild symptoms of acute post traumatic stress disorder. (Mazza, M. G. et al 2020). The prevalence of chronic fatigue syndrome had a correlation with post-traumatic stress disorder (PTSD) in a study conducted after the outbreak of the COVID-19 in Iran (Silmani et al, 2021), that showed 5.8% of subjects suffering from PTSD after 6 months of SARS-CoV-2 infection onset. In this Study we propose to use a tool to quantify the degree of physical and psychological fatigue in post-COVID-19 patients, and assess the correlation of fatigue with the neuropsychiatric sequelae in hospitalized and non hospitalized patients.
Detailed description
This study will address the neuropsychiatric sequelae that remain for at least 6 months after SARS-CoV-2 acute infection, as depression, anxiety and/or post-traumatic stress disorder. The patiensts will be assessed at the post-COVID-19 outpatient clinics of five Portuguese Hospitals. In the first visit (T1) will be collected the demographic characteristics; the medical history; and the screening of acute disease symptoms and severity. In the second visit (T2), the time frame will be at least 6 months after the positive test and no longer than 9 months, a set of structured questionnaires will be provided, including: the Chalder Fatigue Scale, Anxiety and Depression Hospital Scale (HADS), The Posttraumatic Stress Symptoms-14 (PTSS-14) adapted to COVID-19 and the EuroQol 5-Dimensions (EQ-5D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Neuropsychological Sequelae | Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2023-03-30
- Completion
- 2023-04-30
- First posted
- 2022-04-12
- Last updated
- 2023-03-14
Locations
6 sites across 1 country: Portugal
Source: ClinicalTrials.gov record NCT05323318. Inclusion in this directory is not an endorsement.